Update on the role of imaging in management of metastatic colorectal cancer

Radiographics

Volumn 34, Issue 7, 2014, Pages 1908-1928

  Tirumani, Sree Harsha ^a,b   Kim, Kyung Won ^a,b,c   Nishino, Mizuki ^a,b   Howard, Stephanie A ^a,b   Krajewski, Katherine M ^a,b   Jagannathan, Jyothi P ^a,b   Cleary, James M ^a   Ramaiya, Nikhil H ^a,b   Shinagare, Atul B ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM;

CANCER STAGING; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; HUMAN; NEOPLASM METASTASIS; PATHOLOGY;

COLORECTAL NEOPLASMS; CONTRAST MEDIA; DIAGNOSTIC IMAGING; HUMANS; NEOPLASM METASTASIS; NEOPLASM STAGING;

EID: 84910092997     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.347130090     Document Type: Article

References (65)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29.
2. NCCN Clinical Practice Guidelines in Oncology Colon Cancer Version 3.2013. National Comprehensive Cancer Network Web site. http://www.nccn.org/profes sionals/physician_gls/pdf/colon.pdf. Published November 26, 2012. Accessed March 12, 2013.
3. NCCN Clinical Practice Guidelines in Oncology Rectal Cancer Version 4.2013. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf. Published November 26, 2012. Accessed March 12, 2013.
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009;27(22):3677-3683.
5. Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist 2005;10(suppl 3): 40-48.
6. Fowler KJ, Linehan DC, Menias CO. Colorectal liver metastases: state of the art imaging. Ann Surg Oncol 2013;20(4):1185-1193.
7. Chun YS, Vauthey J-N, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 2009;302(21):2338-2344.
8. O'Connor OJ, McDermott S, Slattery J, Sahani D, Blake MA. The use of PET-CT in the assessment of patients with colorectal carcinoma. Int J Surg Oncol 2011;2011:846512.
9. Tirumani SH, Fraser-Hill M, Auer R, et al. Mucinous neoplasms of the appendix: a current comprehensive clinicopathologic and imaging review. Cancer Imaging 2013;13:14-25.
10. Mongan JP, Fadul CE, Cole BF, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 2009;8(2):100-105.
11. Ong KO, Leen E. Radiological staging of colorectal liver metastases. Surg Oncol 2007;16(1):7-14.
12. Rafaelsen SR, Jakobsen A. Contrast-enhanced ultrasound vs multidetector-computed tomography for detecting liver metastases in colorectal cancer: a prospective, blinded, patient-by-patient analysis. Colorectal Dis 2011;13(4):420-425.
13. Mazzoni G, Napoli A, Mandetta S, et al. Intra-operative ultrasound for detection of liver metastases from colorectal cancer. Liver Int 2008;28(1):88-94.
14. Ruzzenente A, Conci S, Iacono C, et al. Usefulness of contrast-enhanced intraoperative ultrasonography (CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy. J Gastrointest Surg 2013; 17(2):281-287.
15. Sica GT, Ji H, Ros PR. CT and MR imaging of hepatic metastases. AJR Am J Roentgenol 2000;174 (3): 691-698.
16. Soyer P, Poccard M, Boudiaf M, et al. Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. Radiology 2004;231(2): 413-420.
17. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging 2005;5(Spec No A):S149-S156.
18. Kulemann V, Schima W, Tamandl D, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol 2011;79(2):e1-e6.
19. Bajpai S, Sahani D. Recent progress in imaging of colorectal cancer liver metastases. Curr Colorectal Cancer Rep 2009;5(2):99-107.
20. Löwenthal D, Zeile M, Lim WY, et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 2011;21(4):832-840.
21. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010;257(3): 674-684.
22. Au-Yeung AW, Luk WH, Lo AX. Imaging features of colorectal liver metastasis in FDG PET-CT: a retrospective correlative analysis between CT attenuation and FDG uptake. Nucl Med Commun 2012;33(4):403-407
23. Xu LH, Cai SJ, Cai GX, Peng WJ. Imaging diagnosis of colorectal liver metastases. World J Gastroenterol 2011;17(42):4654-4659.
24. Robertson DJ, Stukel TA, Gottlieb DJ, Sutherland JM, Fisher ES. Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 2009;115(4):752-759.
25. Adam R, De Gramont A, Figueras J, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 2012;17(10):1225-1239.
26. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005;23(9):2038-2048.
27. Chua TC, Pelz JO, Kerscher A, Morris DL, Esquivel J. Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma. Ann Surg Oncol 2009;16(10): 2765-2770.
28. van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 2012;19(9):2805-2813.
29. Karlo C, Reiner CS, Stolzmann P, et al. CT- and MRI-based volumetry of resected liver specimen: comparison to intraoperative volume and weight measurements and calculation of conversion factors. Eur J Radiol 2010;75(1):e107-e111.
30. Misiakos EP, Karidis NP, Kouraklis G. Current treatment for colorectal liver metastases. World J Gastroenterol 2011;17(36):4067-4075.
31. Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012;32(4): 1387-1395.
32. Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 2012;6: CD006317.
33. Kim YS, Rhim H, Lim HK, Choi D, Lee MW, Park MJ. Coagulation necrosis induced by radiofrequency ablation in the liver: histopathologic and radiologic review of usual to extremely rare changes. RadioGraphics 2011;31(2):377-390.
34. 90Y radioembolization: a comprehensive review and pictorial essay. RadioGraphics 2008;28(1):81-99.
35. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-237.
36. Catenacci DV, Kozloff M, Kindler HL, Polite B. Personalized colon cancer care in 2010. Semin Oncol 2011;38(2):284-308.
37. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? the GERCOR OPTIMOX2 Study. J Clin Oncol 2009;27(34):5727-5733.
38. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006;24(3):394-400.
39. Arnold D, Andre T, Bennouna J, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: results of a randomized phase III intergroup study (TML study). ASCO Meeting Abstracts 2012;30(15 suppl):CRA3503. Available at: http://meetinglibrary .asco.org/content/97866-114.
40. Van Cutsem E, Sobrero AF, Siena S, et al. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). J Clin Oncol 2012;30:3502. Available at: http://meetinglibrary.asco.org/content/94460-114.
41. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 2010;195(2):281-289.
42. Nishino M, Jagannathan JP, Krajewski KM, et al. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 2012;198(4):737-745.
43. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007;25(13): 1753-1759.
44. Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM. Morphology, attenuation, size, and structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 2010;194(6):1470-1478.
45. Smith AD, Lieber ML, Shah SN. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR Am J Roentgenol 2010;194(1):157-165.
46. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18(2): 299-304.
47. Chung WS, Park MS, Shin SJ, et al. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. AJR Am J Roentgenol 2012;199(4):809-815.
48. Anzidei M, Napoli A, Zaccagna F, et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J Comput Assist Tomogr 2011;35(6):690-696.
49. Meijerink MR, van Waesberghe JH, van Schaik C, et al. Perfusion CT and US of colorectal cancer liver metastases: a correlative study of two dynamic imaging modalities. Ultrasound Med Biol 2010;36(10):1626-1636.
50. Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH. Liver metastases in the era of molecular targeted therapy: new faces of treatment response. AJR Am J Roentgenol 2013;201(1):W15-W28.
51. Chikarmane SA, Khurana B, Krajewski KM, et al. What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents. Emerg Radiol 2012;19(6):535-546.
52. O'Connor JP, Rose CJ, Jackson A, et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br J Cancer 2011;105(1):139-145.
53. De Bruyne S, Van Damme N, Smeets P, et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 2012;106(12):1926-1933.
54. Heijmen L, Ter Voert EE, Nagtegaal ID, et al. Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. Eur Radiol 2013;23(3):748-756.
55. Li Z, Bonekamp S, Halappa VG, et al. Islet cell liver metastases: assessment of volumetric early response with functional MR imaging after transarterial chemoembolization. Radiology 2012;264(1):97-109.
56. Cleary JM, Tanabe KT, Lauwers GY, Zhu AX. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist 2009;14 (11):1095-1105.
57. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 2011;258(1):41-56.
58. Tirumani SH, Baez JC, Jagannathan JP, Shinagare AB, Ramaiya NH. Tumor-bowel fistula: what radiologists should know. Abdom Imaging 2013;38(5):1014-1023.
59. Shinagare AB, Howard SA, Krajewski KM, Zukotynski KA, Jagannathan JP, Ramaiya NH. Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol 2012;199(6):1259-1265.
60. Thornton E, Howard SA, Jagannathan J, et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 2012;85(1018):1420-1426.
61. Howard SA, Krajewski KM, Thornton E, et al. Decade of molecular targeted therapy: abdominal manifestations of drug toxicities-what radiologists should know. AJR Am J Roentgenol 2012;199(1):58-64.
62. Package insert. ERBITUX (cetuximab). Branchburg, NJ: Imclone Systems Incorporated Web site. http://www .accessdata.fda.gov/drugsatfda_docs/label /2012/12508 4s225lbl.pdf. Accessed April 5, 2013.
63. Package insert. Vectibix (panitumumab). Thousand Oaks, Calif: Amgen Incorporated Web site. http://www .accessdata.fda.gov/drugsatfda_docs/label/2012 /12514 7s0148lbl.pdf. Accessed Apr 5, 2013.
64. Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review. J Exp Clin Cancer Res 2009;28:113.
65. Bertot LC, Sato M, Tateishi R, Yoshida H, Koike K. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol 2011;21(12):2584-2596.